In a report issued on April 13, Standpoint Research from Standpoint Research maintained a Hold rating on Aphria (APHA), with a price target of C$18.00. The company’s shares closed last Wednesday at $14.23.
Currently, the analyst consensus on Aphria is a Moderate Buy with an average price target of $17.98, a 22.1% upside from current levels. In a report issued on April 13, Canaccord Genuity also downgraded the stock to Hold with a C$17.50 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $32.29 and a one-year low of $2.78. Currently, Aphria has an average volume of 24.23M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aphria, Inc. engages in the production and supply of medical cannabis. It operates through the following segments: Cannabis Operations, Distribution Operations, and Business Under Development. The Cannabis Operations segment produces, distributes, and sells both medical and adult-use cannabis. The Distribution Operations segment are carried out through its wholly owned subsidiaries ABP, FL Group, and CC Pharma. The Distribution Under Development segment includes operations in which the firm has not received final licensing or has not commenced commercial sales from operations. The company was founded by Cole Cacciavillani and John Cervini on June 22, 2011 and is headquartered in Leamington, Canada.
Read More on APHA:
